Log in
Request a free trial
Request a free trial
Log in
Products
Solutions
Data
News & Analysis
About
Blog
News & Analysis
driven by the PitchBook Platform
Articles
reports
All articles
All
Venture Capital
Private Equity
M&A
Tech
Europe
reports
Subscribe
CIR Gives Bluebird Bio Something to Sing About: $9.3M
October 30, 2012
Share:
Gene therapy company
bluebird bio
has been awarded $9.3 million to continue its Phase ½ trial of a stem cell transplant therapy that could aid in the treatment of beta-thalassemia and sickle cell disease. The award came from the
California Institute for Regenerative Medicine
’s Strategic Partnership. Back in July, bluebird secured a hefty $60 million of Series D funding from Deerfield Partners,
RA Capital
,
Ramius Capital Group
,
ARCH Venture Partners
,
Third Rock Ventures
,
TVM Capital
and
Forbion Capital Partners
.
bluebird bio
Pharmaceuticals
Oncology
Cambridge, MA
$9.3 million
Grant
View details
Share:
Tags:
Private Equity,
Venture Capital
Related content
Load more
